Inventiva (IVA) Set to Announce Quarterly Earnings on Wednesday

Inventiva (NASDAQ:IVA) will be issuing its quarterly earnings data after the market closes on Wednesday, March 27th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Inventiva Trading Up 1.6 %

Inventiva stock opened at $3.84 on Monday. Inventiva has a 12 month low of $2.22 and a 12 month high of $5.05. The stock has a 50-day moving average price of $3.76 and a two-hundred day moving average price of $3.98.

Wall Street Analyst Weigh In

IVA has been the subject of several research reports. Stifel Nicolaus dropped their target price on Inventiva from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, February 16th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Inventiva in a research note on Wednesday, March 20th. Finally, Lifesci Capital reaffirmed an “outperform” rating on shares of Inventiva in a research note on Friday, January 5th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $15.67.

Hedge Funds Weigh In On Inventiva

Several institutional investors have recently added to or reduced their stakes in the business. Morgan Stanley increased its holdings in shares of Inventiva by 300.0% during the fourth quarter. Morgan Stanley now owns 6,000 shares of the company’s stock valued at $27,000 after acquiring an additional 4,500 shares in the last quarter. Citigroup Inc. increased its holdings in shares of Inventiva by 91.7% during the first quarter. Citigroup Inc. now owns 23,000 shares of the company’s stock valued at $84,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Commonwealth Equity Services LLC bought a new stake in shares of Inventiva during the first quarter valued at approximately $51,000. 11.46% of the stock is owned by institutional investors and hedge funds.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.